老化剂对SASP细胞因子分泌和CAFs对EMT的调节的差异性影响
Daria A Bogdanova1,2, Ekaterina D Kolosova2, Tamara V Pukhalskaia1,2
1Division of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Krasndarsky Krai, 354340 Sochi, Russia.
International journal of molecular sciences
|April 13, 2024
概括
针对瘤微环境中的衰老细胞的老化药物可以产生相反的效果. 矛盾的是,一些老化药物可能会促进瘤的进展和对治疗的抗性.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤微环境 (TME) 对瘤进展和治疗反应至关重要.
- 细胞衰老及其相关的分泌表型 (SASP) 可以影响瘤发生.
- 老化疗法旨在消除衰老细胞,提供一种新的抗癌策略.
研究的目的:
- 研究两种老化药物 - - 纳维托克拉克斯和达沙替尼/克尔塞丁 - - 对癌症相关纤维细胞 (CAFs) 的差异作用及其在上皮-介质细胞过渡 (EMT) 中的作用.
- 评估老化疗法超越老化细胞枯竭的潜在副作用.
主要方法:
- 癌症相关纤维细胞 (CAFs) 用纳维托克拉克斯或达沙替尼/克尔塞丁治疗.
- 衰老细胞减少的量化.
- 对老化相关分泌表型 (SASP) 组件的分析,特别是IL-6分泌.
- 在MC38结肠直肠癌细胞中评估表皮-介质细胞过渡 (EMT) 和细胞迁移.
主要成果:
- 纳维托克拉克斯和达沙替尼/奎尔塞丁都有效地减少了老化的CAF.
- 与纳维托克拉克斯不同,达沙替尼/克尔塞丁增加了CAFs的IL-6分泌.
- 这种IL-6的增加与MC38癌细胞的增强迁移和EMT相关.
结论:
- 老化药物可以对CAF和促进瘤的过程产生明显的,甚至相反的效果.
- 一些老化剂可能具有促进瘤发生的副作用,独立于它们的老化活性.
- 在临床应用之前,需要对老化剂进行广泛的临床前评估,以了解它们对瘤进展和治疗耐药性的多方面的影响.
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K


